Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.

Abstract: A process for purifying a lipid composition having predominantly neutral lipid components having at least one long chain polyunsaturated fatty acid is disclosed. The process employs contacting the lipid composition with a polar solvent, such as acetone, wherein the solvent is selected such that contaminants are less soluble in the solvent than is the long chain polyunsaturated fatty acid. The process is typically conducted at cooler temperatures, including about 0° C. Upon precipitation of the contaminants from the lipid composition, a separation is conducted to remove the precipitated material from the lipid composition. The long chain polyunsaturated fatty acids can include ARA, DPA, EPA, and/or DHA. The process of the present invention effectively winterizes lipid compositions, thereby reducing the tendency of such compositions to become hazy.

Abstract: The present invention pertains to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucleotides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.

Abstract: An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.

Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.

Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: Methods for the preparation of a free-flowing, storage-stable fatty acid metal salt product by forming a reactive admixture of (a) an unsaturated fatty acid glyceride feedstock; and (b) from about 1 mol to about 3 mol of at least one monovalent metal hydroxide or at least one divalent metal hydroxide; and heating the admixture to a temperature at which said fatty acid glycerides saponify to form fatty acid metals salts; wherein said monovalent metal is potassium; and wherein said divalent metal is selected from the group consisting of calcium, copper, magnesium and zinc. The fatty acid glycerides are saponified in an atmosphere in which the partial pressure of oxygen has been reduced by an amount effective to provide an improvement in storage stability until a free-flowing, storage-stage product is obtained. Storage stable metal salts of unsaturated fatty acids prepared by the inventive methods are also disclosed.

Abstract: The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin.

Abstract: The present invention relates to a fatty acid composition which contains an effective amount of fatty acids providing improved low temperature stability of the composition. The present invention also relates to a process for producing a fatty acid composition wherein the process comprises the steps of selecting a crude tall oil having a fatty acid concentration and type capable of providing low temperature stability, distilling said crude tall oil to provide a fatty acid composition containing an effective amount of tall oil fatty acids providing low temperature stability.

Abstract: A method for identifying the redox activity of a subject compound is disclosed. The method can be performed aerobically and can include forming a mixture comprising a free-radical precursor and a compound to be tested, and converting the free-radical precursor into a free-radical anion and a free-radical cation. After the free radical cation and the free radical anion have been formed, the relative redox activity of the subject compound may cause a difference in the rate of photo-bleaching of the mixture and/or the rate of superoxide generation. These differences can be quantified and used to identify the redox activity of the subject compound. This sensitive technique for measuring redox activity can be used to screen compounds for various biological applications. Drugs also can be developed based on the relationship between redox activity and biological activity for particular biological applications.

Abstract: The present invention relates to processes for obtaining a lipid from a cell by lysing the cell, contacting the cell with a base and/or salt, and separating the lipid. The present invention is also directed to a lipid prepared by the processes of the present invention. The present invention is also directed to microbial lipids having a particular anisidine value, peroxide value, and/or phosphorus content.

Abstract: Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism.

Abstract: Disclosed is an esterification reaction product which is capable of gelling both an oil agent and a cyclic silicone or a volatile dimethylpolysiloxane, or both an oil agent and a nonvolatile dimethylpolysiloxane. Also disclosed are a gelling agent contacting the esterification reaction product, and a cosmetic preparation containing the esterification reaction product or the gelling product and having an excellent feeling of use. Specifically, the cosmetic preparation contains, as a gelling agent, an esterification reaction product which is obtained by esterifying a component A that is a polyhydric alcohol or a condensate thereof, a component B that is a saturated dibasic acid having 10-28 carbon atoms, a component C that is a linear saturated fatty acid having 16-28 carbon atoms, and a component D that is a branched saturated fatty acid having 8-28 carbon atoms at a blending ratio (component A:component B) of 1.0 mole:0.10-0.20 mole.

Abstract: Compounds of formula (I); wherein R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl-DHA, alpha-methyl DHA methyl ester, alpha-methyl-DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed.

Abstract: A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.

Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.

Abstract: A co-salt of a polyunsaturated fatty acid and a non-fatty acid is formed as a precipitate. The co-salt formed is free flowing and does not tend to agglomerate (cake) in storage. The resultant co-salt product will be easy to blend with other products to produce dietary supplements. These novel co-salt products may also tablet very well and may be added to current dietary supplement tablets.

Abstract: The present invention relates to compounds of the following formula (I): where n is an integer between 1 and 15, m is 0, 1, 2 or 3, and R is the hydrocarbon chain of a polyunsaturated fatty acid selected from among omega 3 and omega 6, as well as to pharmaceutical or cosmetic compositions containing same, to a method for preparing and using same, in particular for treating acne and seborrhoeic dermatitis.

Abstract: The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5?-reductase. This is a novel use of compounds of general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—O(?), where R? is chosen from among H, and the alky from C1 to C22, each compound of general formula (I) being used as such or in mixtures with other compounds, as the active principle in a pharmaceutical or cosmetic composition designed to inhibit the action of the enzyme 5?-reductase, and of the pharmaceutical or cosmetic compositions deriving therefrom.

Abstract: Described are a method and a composition for preventing and/or treating a disease related to mitochondrial dysfunction by inhibiting the fatty acid oxidation of one or more cells of an organism. Particularly, the fatty acid oxidation is inhibited by inhibiting the expression and/or activity of the enzyme Camitin-Palmitoyl-Transferase-1 (CPT-1) by means of an arylalkyl- or arlyoxyalkyl-substitued oxirane carboxylic acid or pharmaceutically acceptable salts and derivatives of the arylalkyl-substituted oxirane carboxylic acid.

Abstract: Provided herein are oil compositions comprising an interesterified structured lipid component, the component being an interesterifcation reaction product of an amount of a medium chain triglyceride, an amount of a long chain domestic oil, and an amount of a a source of stearidonic acid. The structured lipid component can be used in edible oil compositions. The oil compositions can contain an amount of a phytosterol ester component. The oil compositions disclosed herein have good stability and also have other properties useful for an edible oil composition.

Abstract: The invention relates to using vegetable oil having a natural viscosity index (VI) of greater or equal to 200 as a pressure medium in hydraulic systems and as a transmission fluid. The vegetable oil has a portion of monounsaturated fatty acids of at least 80%, a portion of double unsaturated fatty acids of 1-10% at maximum, and a portion of triple unsaturated fatty acids of less than 1%, preferably less than 0.1%. Part of the vegetable oil can be used in the form of an unsaturated ester of the vegetable oil. The vegetable oil can also contain an additive in a portion of 2-5% by weight selected from anti-oxidants, copper deactivators, anti-corrosion agents, wear protection agents and anti-foaming agents. The shear stability of the vegetable oil used according to the invention equals 0.7% or less, measured over 20 hours of use.

Abstract: The present invention is directed to an ester that can be used to produce compositions that are soft solids, which comprises an specific solid ester combined with specific liquid esters selected from the group consisting of glyceryl esters, trimethylolpropane esters, and pentaerythritol esters. The compositions containing this ester providing emolliency to the skin by applying the compositions of the present invention. Finally, the invention is also directed to application of sun screen actives, hydroxy acids, antioxidants, flavonoids, tocopherol, vitamins and the like to the skin in gelled form.

Abstract: The invention provides a long acting curcumin derivative, preparation method and pharmaceutical use thereof, wherein said long acting curcumin derivative having the general structural formula disclosed herein, wherein R1 and R2 are hydrogen or methoxyl; R3 and R4 are each independently selected from C1-C50 alkyl. Compared with cuminoids, the inventive long acting curcumin derivative has a better release effect, a higher bioavailability and pharmaceutical activity, and thus can be useful for the treatment of diseases such as depression and cancer.

Abstract: The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called “n-3 PUFA”) as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years.

Abstract: The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.

Abstract: Processes for the enzyme-catalyzed production of triglycerides using polyunsaturated fatty acids, in which (a) the reaction of polyunsaturated fatty acids and/or C1-4 alkyl esters thereof with glycerol in vacuo in the presence of an immobilized enzyme to form their triglycerides is accelerated by addition of an additive from the group of weakly basic salts, complexing agents and ion exchangers and/or addition of a weakly basic salt and/or addition of an entraining agent in the form of a solvent or a gas and/or addition of glycerol-binding adsorbers and/or heat treatment of the partial glyceride intermediate product, (b) the immobilized enzymes are removed from the triglyceride by separation or filtration and (c) the remaining fatty acids and/or C1-4 alkyl esters thereof are removed from the triglyceride by distillation, refining or extraction.

Abstract: The present invention relates to a method for promoting infant feeding, growth or development comprising administering to an infant a formula or a pharmaceutical composition comprising an endocannabinoid in an amount sufficient to promote feeding, growth or development. The present invention also relates to an infant formula comprising an enhanced amount of an endocannabinoid. The infant formula of the invention may be in a powder form or in a liquid form. The infant formula or the pharmaceutical composition may further comprise an endocannabinoid-promoting compound.

Abstract: The present invention relates to nucleic acids derived from Drechslera tritici-repentis, Cylindorcarpon herteronema, Diploida natalensis, Stagonospora nodorum, Microdochium nivalae and Periplaneta americana. The invention also relates to the individual coding sequences and to proteins encoded by these sequences in combination with other sequences as well as to a process for converting oleic acid to linoleic acid to Iinoleic acid and the production of arachidonic acid, eicosapentaenoic acid and/or docosahexaenoic acid in a plant.

Abstract: This invention is in the field of biotechnology, in particular, this pertains to polynucleotide sequences encoding membrane bound O-acyltransferase genes and the use of these acyltransferases for altering fatty acid profiles in oilseed plants. Methods for increasing elongation and desaturation conversion efficiencies are also disclosed.

Abstract: The present invention relates to new substances which are derived from naturally occurring straight-chain and unbranched fatty acids and also from semi-synthetic and synthetic compounds with principally the same structure in that they represent dimers, trimers, tetramers or higher oligomers of the starting substances.

Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterized in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.

Abstract: Aspects of the invention provide methods for differential regulation of fatty acid unsaturation in seed oil and membrane lipids of plants based on modulation of a previously unknown biosynthetic pathway involving a novel phosphatidylcholine: diacylglycerol cholinephosphotransferase (PDCT) that regulates phosphatidylcholine biosynthesis in developing oil seed plants. Specific aspects relate to inventive PDCT polypeptides including, for example, variants, deletions, muteins, fusion proteins, and orthologs thereof (collectively PDCT proteins), to nucleic acids encoding same, to plants comprising such PDCT sequences or proteins or devoid or depleted of such PDCT proteins or sequences, and to methods for generating plants having altered or no PDCT expression and/or activity, including but not limited to methods comprising mutagenesis, recombinant DNA, transgenics, etc.

Abstract: Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its effective component. The composition is expected to reduce the risk in the patient at high risk for occurrence and/or recurrence of a cardiovascular event, and particularly to have a preventive effect on occurrence and/or recurrence of a cardiovascular event in the patient with a high ratio of oleic acid to stearic acid in plasma.

Abstract: The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is —C(?O)Rn and R1, R2R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In Rn, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.

Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).

Abstract: The invention discloses a novel discovery of anti-microbial activity against oral bacteria, which can be applied for controlling and preventing oral diseases, of omega-3, omega-6, and omega-9 fatty acids, but not limited to omega-3, omega-6, and omega-9 fatty acids; omega-3, omega-6, and omega-9 fatty acid methyl esters, and omega-3, omega-6, omega-9 fatty acid ethyl esters and their application method. The application of this discovery includes the preparation of drugs, dietary supplements, food and daily necessities with oral health care and therapeutic effects.

Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Abstract: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 25% eicosapentaenoic acid (EPA, an ?-3 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases and optionally comprise various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of EPA. Production host cells are claimed, as are methods for producing EPA within said host cells.

Abstract: The present invention provides transgenic soybean event MON87769, and cells, seeds, and plants comprising DNA diagnostic for the soybean event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said soybean event in a sample, methods for detecting the presence of said soybean event nucleotide sequences in a sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said soybean event in a sample, growing the seeds of such soybean event into soybean plants, and breeding to produce soybean plants comprising DNA diagnostic for the soybean event.

Abstract: The present disclosure relates to the isolation, purification, and characterization of a diacylglycerol acyltransferase 2 (DGAT2), and genes encoding DGAT2, from algae. DGAT2 can incorporate very long chain polyunsaturated fatty acids in to triacylglycerol more efficiently than DGAT1. The disclosure concerns methods of regulating seed oil content, fatty acid synthesis and fatty acid composition using the DGAT2 gene and to tissues and plants transformed with the gene. The disclosure also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of the disclosure, and a method of producing such plants and plant seeds.

Abstract: The present invention is directed to oil compositions having a high concentration of poly-unsaturated fatty acids. In addition, the oils of the present invention have advantageous stability characteristics and minimal trans-fatty acids.

Abstract: A chewable composition for the oral delivery of plant-based omega fatty acid compounds. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include an organic or in-organic gummy candy made from a binding agent, sweeteners, flavoring, and coloring. The active ingredient may include a plant-based omega fatty acid to provide a desired effect on the user. The delivery vehicle may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, probiotics, prebiotics, antioxidants, amino acids, digestive enzymes, proprietary dietary supplements, or any other health promoting ingredient.

Abstract: Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.

Abstract: An agent for suppressing pollen dispersal, containing an oleic acid derivative or a linoleic acid derivative as an active ingredient, which does not influence the trunk, branches and leaves of trees, shows a sharp efficacy on the male organ and is in the form of a solution or emulsion having solution stability by diluting with water.

Abstract: Disclosed are novel oxylipins that are derived from ?-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

Abstract: Methods for the preparation of a free-flowing, storage-stable fatty acid metal salt product by forming a reactive admixture of (a) an unsaturated fatty acid glyceride feedstock; and (b) from about 1 mol to about 3 mol of at least one monovalent metal hydroxide or at least one divalent metal hydroxide; and heating the admixture to a temperature at which said fatty acid glycerides saponify to form fatty acid metals salts; wherein said monovalent metal is potassium; and wherein said divalent metal is selected from the group consisting of calcium, copper, magnesium and zinc. The fatty acid glycerides are saponified in an atmosphere in which the partial pressure of oxygen has been reduced by an amount effective to provide an improvement in storage stability until a free-flowing, storage-stage product is obtained. Storage stable metal salts of unsaturated fatty acids prepared by the inventive methods are also disclosed.

Abstract: Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta-8 desaturases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these delta-8 desaturases in plants and oleaginous yeast.

Abstract: The present invention provides novel genes for ATP:citrate lyase. A nucleic acid comprising the nucleotide sequence shown in SEQ ID NO: 5, 6, 9 or 10 or a fragment thereof.